Delayed Presentation of Acute Generalized Exanthematous Pustulosis Following Treatment with Cefepime in a Patient with COVID-19 without the Use of Hydroxychloroquine

Acute generalized exanthematous pustulosis induced by Moderna COVID-19 messenger RNA vaccine

“…[4][5][6] Recently, AGEP has been reported in patients with COVID-19 following treatment with hydroxychloroquine and cefepime. 7,8 A late-onset AGEP-like vesicular cutaneous eruption has also been reported in a patient months after SARS-CoV-2 infection. 9 Overall, only a handful of cases of AGEP after SARS-CoV-2 infection have been described in the literature.…”

COVID-19 presenting as acute generalized exanthematous pustulosis associated with multiorgan dysfunction in a 44-year-old female patient

“…This case is unique with respect to disease severity leading to haemodynamic instability and multiorgan dysfunction. To the best of our knowledge, there is only one reported case of AGEP in patients with SARS-CoV-2 infection with no prior exposure to hydroxychloroquine (but related to cefepime administration), with some antimalarial-related cases reported in the medical literature [9][10][11] . SARS-CoV-2 skin manifestations are variable, from mild manifestations such as perniosis with generally foot compromise, moderate involvement due to morbilliform, vesicular or urticarial eruption and more severe involvement in relation to cutaneous vasculitis.…”

Acute generalized exanthematous pustulosis following treatment with favipiravir in a patient with COVID‐19 without hydroxychloroquine use: Report of the first case

“…6 Delayed presentation (after 7 days) in cefepime secondary AGEP in a case of COVID-19 patient has been reported. 2 Our case has presented with AGEP 16 days after treatment which was a longer latency period compared to AGEP reported in COVID-19 infected patients in the recent literature. We hypothesize that combination of favipiravir and genetic disposition with COVID-19 induced cytokine storm led to delayed development of AGEP in our case.…”

“…generalized exanthematous pustulosis (AGEP) has been reported in COVID-19 patients, mostly associated with hydroxychloroquine (HCQ). There are few AGEP cases in COVID-19 patients reported due to β-lactam antibiotics 2,3 in the literature. Herein, we report the first case of favipiravir-induced AGEP with histologic findings.…”